

*This content has neither been reviewed nor approved by MCG Health.*

## SHP Anti- Phospholipid Antibody Testing

AUTH: SHP Medical 287 v5 (AC)

**MCG Health**  
Ambulatory Care  
26th Edition

[Link to Codes](#)

- [Coverage](#)
- [Application to Products](#)
- [Authorization Requirements](#)
- [Description of Item or Service](#)
- [Exceptions and Limitations](#)
- [Clinical Indications for Procedure](#)
- [Document History](#)
- [Coding Information](#)
- [References](#)
- [Codes](#)

---

### Coverage

[Return to top of SHP Anti- Phospholipid Antibody Testing - AC](#)

See the appropriate benefit document for specific coverage determination. Member specific benefits take precedence over medical policy.

---

### Application to Products

[Return to top of SHP Anti- Phospholipid Antibody Testing - AC](#)

Policy is applicable to all products.

---

### Authorization Requirements

[Return to top of SHP Anti- Phospholipid Antibody Testing - AC](#)

Pre-certification by the Plan is required.

---

### Description of Item or Service

[Return to top of SHP Anti- Phospholipid Antibody Testing - AC](#)

Anti-phospholipid antibody testing is a blood test to determine possible diseases.

---

### Exceptions and Limitations

[Return to top of SHP Anti- Phospholipid Antibody Testing - AC](#)

- There is insufficient scientific evidence to support the medical necessity of the following Anti- Phospholipid Antibody Testing as it is not shown to improve health outcomes upon technology review:
  - PROTHROMBIN Antibodies IGG
- There is insufficient scientific evidence to support the medical necessity of Anti-phosphatidylserine (phospholipid) antibody testing (e.g. cardiolipin (e.g. IgG, IgM) for uses other than those listed in the clinical indications for procedure section.

---

### Clinical Indications for Procedure

[Return to top of SHP Anti- Phospholipid Antibody Testing - AC](#)

- Anti- phospholipid antibody testing is considered medically necessary for **ALL** of the following
  - Individual is suspected of having antiphospholipid syndrome as indicated by **1 or more** of the following
    - Vascular thrombosis
    - Unexplained, recurrent fetal loss
    - Autoimmune thrombocytopenia
  - Testing is not for infertility
  - Testing is for **1 or more** of the following
    - Lupus (e.g. RVVT, hexagonal phase lipid neutralization) testing
    - Anti-beta2 glycoprotein I antibodies testing
    - Anti-phosphatidylserine (phospholipid) antibody testing (e.g. cardiolipin (e.g. IgG, IgM)
- Anti- Phospholipid Antibody Testing is **NOT COVERED** for **ANY** of the following
  - PROTHROMBIN Antibodies IGG

---

### Document History

[Return to top of SHP Anti- Phospholipid Antibody Testing - AC](#)

- Revised Dates:
  - 2021: April, September
  - 2020: January, November
  - 2016: February, March
  - 2015: May
  - 2014: May, July, September, November, December
  - 2013: February, March, April, July, October
  - 2012: March
  - 2011: December
  - 2009: March
- Reviewed Dates:
  - 2023: April
  - 2022: April
  - 2020: May
  - 2018: September
  - 2017: December
  - 2016: April, May
  - 2012: August
  - 2011: March

- 2010: March
- Effective Date: March 2008

## Coding Information

[Return to top of SHP Anti- Phospholipid Antibody Testing - AC](#)

- CPT/HCPCS codes covered if policy criteria is met:
  - CPT 86146 - Beta 2 Glycoprotein I antibody, each
  - CPT 86147 - Cardiolipin (phospholipid) antibody, each Ig class
  - CPT 86148 - Anti-phosphatidylserine (phospholipid) antibody
- CPT/HCPCS codes considered not medically necessary per this Policy:
  - None

## References

[Return to top of SHP Anti- Phospholipid Antibody Testing - AC](#)

References used include but are not limited to the following:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; Uptodate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2022). Retrieved Feb 16, 2023, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=anti-phospholipid&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance>

(2022, Aug 31). Retrieved Feb 16, 2023, from MCG: <https://careweb.careguidelines.com/ed26/index.html>

(2022). Retrieved Feb 16, 2023, from Food and Drug Administration: [https://www.google.com/search?q=FDA+approval+for+anti-phospholipid+antibodies&safe=strict&rlz=1C1GCEA\\_enUS982US982&sxsr=AJOqlzXF1YFgaEHnvKQDGKe8qM\\_UAmDA:1676581268152&ei=JnuY4b4Cl2vqtsPw7GM4A4&start=10&sa=N&ved=2ahUKEwQ8tMDegQ](https://www.google.com/search?q=FDA+approval+for+anti-phospholipid+antibodies&safe=strict&rlz=1C1GCEA_enUS982US982&sxsr=AJOqlzXF1YFgaEHnvKQDGKe8qM_UAmDA:1676581268152&ei=JnuY4b4Cl2vqtsPw7GM4A4&start=10&sa=N&ved=2ahUKEwQ8tMDegQ)

(2023). Retrieved Feb 16, 2023, from Hayes, Inc: <https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522Beta%2520%2520Glycoprotein%2520I%2520antibody%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%2522%2522page%2522:0,%2522size%2522:50%252D,%2522type%2522:%2522>

(2023). Retrieved Feb 16, 2023, from AIM Specialty Health: <https://aimspecialtyhealth.com/resources/clinical-guidelines/>

(2023). Retrieved Feb 16, 2023, from National Comprehensive Cancer Network: <https://www.nccn.org/search-result?indexCatalogue=nccn-search-index&searchQuery=anti-phospholipid>

Erkan, D., & Ortel, T. (2022, Nov 08). Diagnosis of antiphospholipid syndrome. Retrieved Feb 16, 2023, from UpToDate: [https://www.uptodate.com/contents/diagnosis-of-antiphospholipid-syndrome?search=Anti-phospholipid%20syndrome&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1#H2187626790](https://www.uptodate.com/contents/diagnosis-of-antiphospholipid-syndrome?search=Anti-phospholipid%20syndrome&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H2187626790)

EULAR recommendations for the management of antiphospholipid syndrome in adults. (2019). Retrieved Feb 16, 2023, from European Alliance of Associations for Rheumatology: <https://ard.bmj.com/content/annrheumdis/early/2019/05/14/annrheumdis-2019-215213.full.pdf>

Procedure Fee Files & CPT Codes. (2023). Retrieved Feb 16, 2023, from Department of Medical Assistance Services: <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT>

Rodziewicz, M., & D'Cruz, D. (2020, Apr 07). An update on the management of antiphospholipid syndrome. Retrieved Feb 16, 2023, from PubMed: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236388/>

Vandevelde, A., & Devreese, K. (2022, Apr 13). Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances. Retrieved Feb 16, 2023, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/35456258/>

Antiphospholipid Syndrome (2021). Retrieved Apr 11, 2022, from American College of Rheumatology: <https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Antiphospholipid-Syndrome>

Antiphospholipid Antibody Syndrome (APS). (2022, Feb 14). Retrieved Apr 11, 2022, from DynaMed: [https://www.dynamedex.com/condition/antiphospholipid-antibody-syndrome-aps#TOPIC\\_LJS\\_D2R\\_CGB](https://www.dynamedex.com/condition/antiphospholipid-antibody-syndrome-aps#TOPIC_LJS_D2R_CGB)

Procedure Fee Files & CPT Codes. (2022). Retrieved Apr 11, 2022, from Department of Medical Assistance Services: <https://www.dmas.virginia.gov/for-providers/procedure-fee-files-cpt-codes/#searchCPT>

Tumian, N., & Hunt, B. (2022, Jan 29). Clinical Management of Thrombotic Antiphospholipid Syndrome. Retrieved Apr 11, 2022, from PubMed: <https://pubmed.ncbi.nlm.nih.gov/35160188/>

## Codes

[Return to top of SHP Anti- Phospholipid Antibody Testing - AC](#)

**CPT® : 86146, 86147, 86148**

*CPT copyright 2022 American Medical Association. All rights reserved.*

MCG Health  
Ambulatory Care 26th Edition